IRIda Houtved Rasmussen

Ida Houtved Rasmussen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ida Houtved Rasmussen has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Top Cited Papers

    Patient‐Related Predictors of Opioid Use, Pain and Opioid‐Related Adverse Events in the First 24 h After Surgery: A Systematic Review and Meta‐Analysis

    by Caroline Risegaard Folkersen, Ida Houtved Rasmussen, Pernille Bjersand Sunde, Selma Pedersen Kjartansdóttir, Atena Saito, Markus Harboe Olsen, Jens Laigaard, Mathias Maagaard, Ole Mathiesen, Anders Peder Højer Karlsen

    Background and Objectives: Acute postoperative pain is typically managed with titration of opioids, balancing pain intensity and opioid‐related adverse events (ORADEs). Often, the dosing strategy is individualised based on the clinician's intuition or expertise. The influence of broader patient‐related predictors remains insufficiently synthesised. This systematic review aimed to synthesise evidence on associations between patient‐related predictors and opioid use, pain intensity and ORADEs within 24 h after surgery. Databases and Data Treatment: In this systematic review, we searched MEDLINE, Embase and CENTRAL for studies examining associations between patient‐related predictors and opioid use, pain, or ORADEs within 0–24 h postoperatively. We used Quality in Prognosis Studies (QUIPS) for risk of bias and conducted meta‐analyses. Results: We included 39 studies (294,221 patients) investigating 31 patient‐related predictors. Meta‐analyses showed that young age and chronic pain were associated with moderate–severe pain risk and large opioid consumption. Smoking, non‐normal BMI, anxiety and preoperatively opioid use or pain were associated with moderate–severe pain. Female sex and lower ASA‐scores were associated with postoperative nausea and vomiting. No other ORADEs were assessed. All but two studies were high risk of bias. Conclusion: The certainty of evidence was low due to high risk of bias and substantial heterogeneity in designs, populations and exposure/outcome definitions. Within 24 h after surgery, younger age, female sex, lower ASA score, smoking, abnormal BMI, anxiety, chronic pain and chronic opioid use were associated with greater postoperative complexity in terms of increased pain intensity, opioid use, or risk of nausea and vomiting. Significance Statement: This comprehensive review provides important understanding of patient‐related predictors, which can contribute to a more individualised perioperative pain management, including dosing of preventive analgesia at the end of surgery and in adjusting as‐needed opioid doses postoperatively. Prospero‐Identifier: CRD42024559821.


  • Pharmacogenetic Predictors of Postoperative Opioid‐Related Adverse Events: A Systematic Review

    by Selma Pedersen Kjartansdóttir, Caroline Folkersen, Ida Houtved Rasmussen, Pernille Bjersand Sunde, Atena Saito, Mathias Maagaard, Michael Asger Andersen, Kim Peder Dalhoff, Anders Peder Højer Karlsen

    Backgrounds/Aims: This systematic review aimed to assess associations between genotypes and the risk of experiencing postoperative opioid‐related adverse drug events (ORADEs). Methods: Following PRISMA guidelines and registered with PROSPERO, we searched MEDLINE, Embase and CENTRAL for studies assessing genetic predictors of ORADEs within 24 h postoperatively. Eligible studies included English‐written retrospective and prospective cohort studies as well as randomised trials. Risk of bias was assessed using the QUIPS tool. Data were extracted in duplicate, and relative risks with 95% confidence intervals were calculated. Meta‐analyses were conducted when ≥ 2 studies assessed the same genetic predictor and ORADE relationship. Results: Of the 119 523 citations, 27 studies (5279 patients) met inclusion criteria. All included studies ranked high risk of bias. Of the 28 investigated predictors, 17 significantly increased or decreased ORADE risk in individual studies. Of the 31 meta‐analyses, only two demonstrated significant associations ( p < 0.05; COMT rs4680 AA and nausea, and CYP2D6 IM and hyperhidrosis). Conclusion: While finding two significant associations, we would expect one to two significant associations at random given the 31 meta‐analyses. Findings were limited by heterogeneity, few studies and small sample sizes. The current evidence does not suggest that genotypes should have a central place in the risk stratification of the occurrence of postoperative ORADEs.


  • Decision Support Tools for Adjusting Perioperative Opioid Dosing as Individualised Postoperative Pain Management: A Systematic Review

    by Pernille Bjersand Sunde, Ida Houtved Rasmussen, Caroline Folkersen, Atena Saito, Markus Harboe Olsen, Jens Laigaard, Nicholas Papadomanolakis‐Pakis, Troels Haxholdt Lunn, Christian S. Meyhoff, Ole Mathiesen, et al.

    Introduction: Despite decades of efforts to optimize procedure‐specific pain management, up to 60% of surgical patients still experience moderate to severe pain and opioid‐related adverse effects. Current guidelines primarily rely on standardised dosing protocols rather than individual patient characteristics, offering limited support for tailoring opioid therapy to patient‐specific needs. This systematic review aimed to identify studies on decision support tools for adjusting perioperative systemic opioid dosing as individualised postoperative pain management and evaluate their effects on postoperative outcomes. Methods: We searched EMBASE, MEDLINE and Cochrane Library up to August 2025 for studies including adult surgical patients developing, validating or testing decision support tools (prediction models or nociception monitoring systems). Prediction model studies had to include at least two predictors and target the first 24 postoperative hours. Intervention studies had to report pain, opioid use, or opioid‐related adverse events within 24 h. Studies on chronic pain, intraoperative‐only agents (e.g., remifentanil), or unpublished literature were excluded. Risk of bias was assessed using the Prediction model Risk of Bias Assessment Tool in prediction model studies and Cochrane Risk of Bias and ROBINS‐I tool in intervention studies. We conducted meta‐analyses for intervention studies (RCTs only) when outcomes were comparable. Results: We included 19 studies on decision support tools for perioperative opioid management: seven development and one impact study on personalised prediction models and 11 intervention studies on nociception monitoring systems. All prediction model studies predicted postoperative opioid requirements, had a high risk of bias, limited external validation and poor overall performance (R 2 range: 0.100–0.313). None were clinically tested or provided advice on optimal opioid dosing. For intervention trials evaluating nociception monitoring systems, meta‐analyses showed no significant effect on pain, opioid use, or opioid‐related adverse events within 24 h after surgery. No studies tested risk stratified/individualised opioid treatment. Conclusion: No prediction model study provided concrete guidance for individualising systemic opioid treatment. Nociception monitor–guided opioid doses did not improve acute postoperative pain, opioid use or opioid‐related adverse events. Editorial Comment: This systematic review assessed if available tested prediction models for individual guiding of opioid analgesic dosing, including monitors designed to assess nociceptive signal influence on clinical status, were of benefit in clinical practice. Findings, for outcomes analgesic effect, opioid dosing, or adverse events related to opioids, none of the models or systems have been demonstrated to have cliear clinical utility for optimizing opioid dosing.


  • Minimal Important Difference for Rescue Opioid Consumption in Adults With Acute Pain: A Scoping Review

    by Atena Saito, Jens Laigaard, Pernille Bjersand Sunde, Caroline Folkersen, Ida Houtved Rasmussen, Selma Pedersen Kjartansdóttir, Ole Mathiesen, Anders Karlsen

    Background: The minimal important difference (MID) is established for pain intensity scores in acute pain management, but not for rescue opioid consumption. This scoping review aimed to estimate the MID in rescue opioid consumption for acute pain among adult patients in the postoperative and emergency settings. Methods: We searched MEDLINE, Embase, CENTRAL, clinicaltrials.gov and clinicaltrialsregister.eu for studies published in English from inception to May 2024. We included studies investigating the MID of rescue opioid consumption in adults with acute pain in the postoperative and emergency settings. Because limited studies explicitly investigated the MID, we also included studies assessing the dose–response relationship between opioid consumption and relevant anchors (e.g., pain intensity scores). The primary outcome was MID for 0–24 h rescue opioid consumption; secondary outcomes included longer postoperative periods. Results: We screened 11,748 citations and included 14 studies (8190 patients). Three studies explicitly evaluated MID for rescue opioid consumption. In the remaining 11 studies, we estimated the MID using a 10‐point difference (0–100 scale) in pain intensity score as an anchor. The anchor‐based estimates ranged from 2 to 5 mg IV morphine equivalents, varying by population, method and context. Conclusions: Based on the currently available evidence, we propose a provisional MID of 5 mg IV morphine equivalent in rescue opioid consumption for acute pain. This is lower than the value used in most sample size calculations. Significance Statement: These results can guide sample size calculations and support patient‐centered approaches in acute pain settings. Trial Registration: PROSPERO identifier: CRD42024547409


  • Open Access

    External Validation of an Algorithm to Guide Opioid Administration at the End of Surgery—Protocol for an Observational Cohort Study of the OPIAID Algorithm

    by Anders Peder Højer Karlsen, Pernille Bjersand Sunde, Ida Houtved Rasmussen, Caroline Folkersen, Trang Xuan Minh Tran, Markus Kien Trung Nguyen, Line Maria Elkjær, Troels Haxholdt Lunn, Christian S. Meyhoff, Jonas Valbjørn Andersen, et al.

    Background: Despite advances in pain management, inadequate pain relief and opioid‐related adverse events remain common challenges in perioperative care, often contributing to prolonged recovery and reduced quality of life. The perioperative opioid algorithms for individualized dosing (OPIAID) project aims to develop machine‐learning algorithms tailored to provide patient‐specific opioid dosing across the different phases of perioperative care. For each phase, eight models are trained on granular data from 1.1 million surgical procedures, including demographic and surgical details, vital signs, administered analgesics, pain, and opioid‐related adverse events. The two most accurate models will proceed to external validation. The best‐performing model will subsequently be tested as a decision support against current standard of care.Objectives: This protocol describes the design and external validation of the intraoperative OPIAID algorithm, which suggests the end‐of‐surgery opioid dose intended for postoperative analgesia by approximating clinical performance and evaluating reliability, agreement, and calibration.Methods: In this multicenter, TRIPOD+AI‐adherent, prospective observational cohort study, we will collect data from a diverse surgical population of 656 adult patients undergoing elective or acute surgery under general anesthesia. All patients will require intraoperative opioid administration at the end of surgery for postoperative pain management and a subsequent stay in the post‐anesthesia care unit. The cohort will be used to externally validate two machine‐learning models through standardized measures of reliability, agreement, and calibration, and thereby designate the intraoperative OPIAID algorithm. Subsequently, the cohort will be used to approximate the clinical efficacy, safety and overall performance of the intraoperative OPIAID algorithm's recommended doses versus the clinician‐administered doses. These comparisons will be based on each approach's proximity to a golden standard “optimal dose,” which is calculated based on a predefined generic ruleset incorporating intraoperative opioid dosing, postoperative pain, opioid‐related adverse events, and need for rescue opioid administrations.Conclusion: The intraoperative OPIAID algorithm is intended as a clinical decision aid for anesthesiologists and nurse anesthetists in providing adequate postoperative pain management.